HROW HARROW, INC.
FY2025 10-K
HARROW, INC. (HROW) filed its fiscal year 2025 10-K annual report with the SEC on Mar 2, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: U.S. ophthalmic disease management with FDA-approved branded pharmaceuticals and ophthalmology-focused pharmaceutical compounding
- • New product emphasis: Commercial launches planned for BYOOVIZ and BYQLOVI in mid-2026; OPUVIZ expected mid-2027; MELT-300 sedation tablet with FDA NDA filing expected H1 2027
Management Discussion & Analysis
- • Revenue $272.3M up 36% YoY from $199.6M; IHEEZO sales $81.3M (+65% YoY), VEVYE sales $88.7M (+216% YoY), Other branded sales down $12.5M
- • Gross margin branded 81.0% vs 81.3% prior year, ImprimisRx margin 59.9% down from 67.0%, net loss narrowed to $5.1M from $17.5M
Risk Factors
- • Legal risk: Ocular Science lawsuit with $11.25M judgment after punitive damages reduction and pending appeal filed October 9, 2025
- • Macroeconomic risk: Sole U.S. revenue and asset concentration with 90% accounts receivable from three customers as of December 31, 2025
Get deeper insights on HARROW, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.